

PROGRESSIVE'S EVENING STROLL

DATE: 25 May, 2026

Market Snapshot:

The day belonged to the Bulls. After a strong start, the Index compounded its gains before it started to consolidate until mid-session. In the last session, a sharp uptick in the Banking counters supported the Index in breaching its intraday congestion to close higher at 24,031.70 with gains of 312.40 points. Except for FMCG, all sectors ended the session with gains, with PSU Banks and BankNifty as the top performers, followed by Auto and Capital Markets. In the broader markets, Smallcaps performed in line with the Benchmark Index, while Midcaps lagged.

HOW THE DAY TRENDED



INDICES			
Index	Close	Points	%Chg.
Sensex	76488.96	1073.61	1.42
Nifty50	24031.70	312.40	1.32
Nifty Midcap 100	61966.60	577.30	0.94
Nifty Small Cap 100	18202.70	246.50	1.37

SECTORAL GAINERS / LOSERS			
Sectors	Close	Points	%Chg.
NIFTY PSU BANK	8238.10	231.95	2.90
NIFTY BANK	55293.65	1238.30	2.29
NIFTY AUTO	26463.05	445.95	1.71
NIFTY FMCG	50157.75	(92.05)	(0.18)

NIFTY TOP GAINERS / LOSERS					
Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
EICHER MOTORS	7414.00	6.19	MAX HEALTHCARE	1000.85	(2.19)
ADANI ENT	2849.70	4.87	ONGC	284.95	(1.74)
BAJAJ FINANCE	941.90	2.77	HINDALCO	1099.60	(0.87)
LT	4033.40	2.72	NESTLE IND	1413.60	(0.67)

INDICES LEVELS FOR May 26, 2026

Nifty (future)	
Resistance	24300
Support	23940

Bank Nifty (future)	
Resistance	56120
Support	54850



KEY TAKEAWAYS OF THE DAY

◆ **Lupin receives China approval for Oseltamivir Phosphate Oral Suspension:**

Lupin announced that China's National Medical Products Administration has approved its ANDA for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, a leader in China's paediatric medicine market. This marks Lupin's first product entry into China, a significant milestone in its global expansion. Oseltamivir Phosphate for oral suspension, 6 mg/mL will be launched and commercialized to expand access, particularly for paediatric use. This expands Lupin's global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need.

◆ **USFDA classifies Telangana facility as OAI for Aurobindo Pharma:**

The USFDA conducted an inspection at Unit-I, a formulation manufacturing facility of the company's wholly owned subsidiary, Eugia Pharma Specialities, located in Telangana, between February 16 and February 27, 2026. Following the inspection, the regulator issued four observations to the facility. FDA has now determined that the inspection classification of this facility is "official action indicated" (OAI).

◆ **CCI approves Lemon Tree Hotels' Fleur Hotels stake acquisition and group restructuring via amalgamation and demerger:**

Lemon Tree Hotels Limited has received the detailed order from the CCI regarding the acquisition of equity shares of its material subsidiary, Fleur Hotels Limited, and the internal restructuring of the company group. The approval was granted under Section 31(1) of the Competition Act, 2002, on May 22, 2026. The regulatory approval covers two primary actions. First, it sanctions the acquisition of certain equity shares of Fleur Hotels by Coastal Cedar Investments B.V. Second, it permits the internal restructuring of the Lemon Tree Hotels group through amalgamations and demerger.

◆ **Glenmark USA enters into an agreement with State Attorneys:**

Glenmark Pharma said its subsidiary, Glenmark USA, has agreed to enter into a settlement with state attorneys general for a total amount of USD29.628mn, payable in annual instalments over five years. The settlement remains subject to court approval. The company clarified that Glenmark USA denies all allegations made against it, and the settlement does not constitute any admission of liability, wrongdoing, or illegality.

◆ **IRFC to raise ECB loan worth USD2bn to finance large infra projects:**

Indian Railway Finance Corporation is planning to mobilise USD2bn through external commercial borrowing, primarily in Japanese yen, to fund business growth in the current financial year. The external commercial borrowing (ECB) is part of the Rs70,000cr resource mobilisation plan approved by the board of Indian Railway Finance Corporation (IRFC) for the ongoing financial year. It has signed a loan agreement with the consortium of banks for raising an ECB loan of JPY equivalent USD1.1bn. Given the pipeline of projects, we expect disbursements within the June quarter itself.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com

